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Abstract
Allogeneic human mesenchymal stem cells (hMSCs) can suppress graft versus host disease (GvHD) and have
profound anti-inflammatory and regenerative capacity in stroke, infarct, spinal cord injury, meniscus regeneration,
tendinitis, acute renal failure, and heart disease in human and animal models of disease. There is significant clinical
hMSC variability in efficacy and the ultimate response in vivo. The challenge in hMSC based therapy is defining the
efficacy of hMSC in vivo. Models which may provide insight into hMSC bioactivity in vivo would provide a means
to distinguish hMSCs for clinical utility. hMSC function has been described as both regenerative and trophic
through the production of bioactive factors. The regenerative component involves the multi-potentiality of hMSC
progenitor differentiation. The secreted factors generated by the hMSCs are milieu and injury specific providing
unique niches for responses in vivo. These bioactive factors are anti-scarring, angiogenic, anti-apoptotic as well as
regenerative. Further, from an immunological standpoint, hMSC’s can avoid host immune response, providing
xenographic applications. To study the in vivo immuno-regulatory effectiveness of hMSCs, we used the ovalbumin
challenge model of acute asthma. This is a quick 3 week in vivo pulmonary inflammation model with readily acces-
sible ways of measuring effectiveness of hMSCs. Our data show that there is a direct correlation between the tradi-
tional ceramic cube score to hMSCs attenuation of cellular recruitment due to ovalbumin challenge. The results
from these studies verify the in vivo immuno-modulator effectiveness of hMSCs and support the potential use of
the ovalbumin model as an in vivo model of hMSC potency and efficacy. Our data also support future directions
toward exploring hMSCs as an alternative therapeutic for the treatment of airway inflammation associated with
asthma.
Introduction
Human mesenchymal stem cells (hMSCs) from marrow
reside in situ as pericytes that are hypothesized to func-
tion as sentinels to guard against self-surveillance by
T-cells at sites of tissue damage [1]. The local titers of
hMSCs depend on the vascular density at that site and
on other factors. Although hMSCs were first thought to
function as the source for cellular replacement therapies,
their immuno-modulatory and trophic activities have the
potential for profound therapeutic impact in diseases
associated with sustained inflammation. By providing
additional hMSCs through systemic routes, both
immuno-regulatory and regenerative trophic activities
at sites of inflammation and tissue damage can be
enhanced [2].
hMSCs are non-hematopoietic, multi-potent progeni-
tor cells, which have the ability to influence immune
effector cell development, maturation and function as
well as allo-reactive T-cell responses through the pro-
duction of bioactive cytokines and proteins [3]. The des-
ignation of hMSCs is based upon extensive
immunophenotyping using surface antigens and ability
to function in in vitro models [4]. MSCs are immuno-
modulatory and express no MHC class II, making
hMSCs a viable therapeutic across tissue typing [5,6].
hMSCs produce large quantities of bioactive factors
which provide molecular signatures for the pathway and
activity status of the responding cells [7,8]. These bioac-
tive factors are anti-scarring, angiogenic, anti-apoptotic
and regenerative (i.e., mitotic for host-derived progenitor
cells). As evidence of the profound effect of hMSCs on
the immune system, our colleagues and others have
reported that hMSCs are well tolerated and therapeuti-
cally active in immuno-competent rodent models of
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multiple sclerosis and stroke [9-11]. Thus, xenogenic
hMSCs repress host immunological surveillance in
rodents while at the same time producing reparative
growth factors.
An important issue in hMSC biology has been under-
standing the significant variability among cell prepara-
tions. Models need to be developed which not only
show the relative unique therapeutic application of
hMSCs, but also measure in vivo function (i.e., thera-
peutic potency). Acute (short-term) in vivo models of
inflammation have the potential to provide vehicles for
hMSC efficacy assessment. Although chronic (long-
terms) models provide valid options for study, our focus
was on an in vivo model which would provide a quick
answer of hMSC activity, with the clinical and therapeu-
tic applications in mind. Culture-expanded hMSCs
increase in size with each passage and thus, on a size
basis alone are observed to lodge in the lungs in sub-
stantial numbers when given intravenously [12]. hMSCs
have the potential to provide a local source of trophic
factors in the pulmonary environment, which may result
in changes in lung inflammation [13]. This circumstance
allows us to determine the effects of hMSCs in the
initiation of inflammatory lung diseases and to establish
the criteria for efficacy of different donor hMSCs on
early stages of asthma in rodent models.
Acute bronchial asthma has been characterized by
allergic airway inflammation, which induces both cytolo-
gical as well as histological changes in the airway struc-
ture over time [14]. The pathogenic characteristics of
allergic asthma are associated with airway inflammation
and infiltration of mast cells, basophils, eosinophils,
monocytes and T helper type 2 lymphocytes, along with
the production of isotype-specific immunoglobulin E
(IgE) [15,16]. Several animal models have been developed
to model human airway disease associated with acute
asthma, which have the capacity to mimic the histological
and pathologic changes in the lung. A commonly used
model to study airway inflammation in vivo involves pri-
mary sensitization with ovalbumin (OVA) followed by
daily intranasal challenge with the antigen to generate
airway inflammation mimicking the acute asthma exacer-
bation. This short-term model can provide the basis for
studying the trophic impact of lodged hMSCs on devel-
opment of lung inflammation associated with acute
asthma challenge and the potential benefit of hMSCs in
circumventing acute asthmatic inflammatory disease.
The results of these studies provide the foundation for
understanding the role of hMSCs in altering inflamma-
tory processes in vivo and provide support for the utili-
zation of the short-term acute asthma model as a
validation tool for hMSC efficacy and function in vivo.
Materials and methods
Mouse Model
Balb/c mice were purchased from the Jackson Labora-
tories (Bar Harbor, Maine) at 5 weeks, allowed to
adjust to environment for 1 week. On day 0 (6 weeks
of age) mice were sensitized by intra-peritoneal injec-
tions (100 μL) of 10 μg of ovalbumin (OVA) emulsified
in 1.5 mg of Al (OH)3. On day 14, mice were exposed
to 1% wt/vol OVA [17,18] in sterile saline by aerosoli-
zation every day for 5 days. Sham sensitization and
sham challenges were carried out with sterile saline.
hMSCs were given on either day 14 or day 16 by tail
vein injection with 1 × 106 hMSC/mouse in 100 ul of
PBS. For each of a minimum of 3 experiments, 4-6
animals were evaluated for the following: saline chal-
lenge, saline challenge +hMSC, ovalbumin challenge,
ovalbumin challenge+hMSCs. In addition, subsets of
saline and ovalbumin mice were given bone marrow
derived macrophages (BMDM) as a control for the
hMSC. As a positive control for immunosuppression, a
subset of the ovalbumin sensitized, ovalbumin chal-
lenged mice received dexamethasone at 10 mg/kg. In
all cases, the dexamethasone significantly decreased
total cell recruitment and eosinophil counts (data not
shown) supporting our ability to measure changes in
airway inflammation.
Lung Inflammation
Mice were injected subcutaneously with ketamine (80
mg/kg) and xylazine (10 mg/kg). The thoracic cavity
was opened and lungs exposed. Bronchoalveolar lavage
(BAL) was performed by inserting a cannula through a
cut in the trachea into the bronchi and infusing 3 × 1
ml aliquots of warm PBS containing 0.2% lidocaine. The
BAL fluid sample was recovered by aspirating the liquid
with a syringe. Cells were separated from lavage fluid
and differential analysis was evaluated using cytospins
and Wright-Giemsa staining. Remaining cells were fro-
zen for future analysis. BAL fluid was frozen at -80°C
until assessment for cytokines.
Lung Pathology
Lungs were either perfused with 10% formalin or snap
frozen. Mean viability of lavage cells was > 95% by try-
pan blue dye exclusion. Animals were assessed for
inflammation by BAL and a separate set of animals was
evaluated for lung histology using H&E and trichrome
staining.
Systemic Inflammation
Animals underwent cardiac puncture after completion
of lavage and the blood was processed to obtain serum
and plasma. Serum cytokines were measured using ELI-
SAs or Luminex technology.
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MSCs
Cells were isolated from the marrow of healthy volun-
teers as described elsewhere [19]. Briefly, the marrow
aspirates were layered on density gradients, and the light
cell fraction was retrieved, washed and plated in selected
batches of 10% fetal bovine serum (FBS) in Dulbecco’s
Modified Eagle Medium (DMEM) [20]. Within 14 days
the colony-forming units were selectively expanded to
near confluency and the cells were then lifted from the
dish with trypsin and replated at 4500 cells/cm2 to
ensure they maintained active cell division. As deter-
mined by other studies, cells cultured using this proto-
col were homogenous when FAC-Sorted using over 100
different cell surface antibodies [4]. All 7 hMSCs pre-
parations were harvested from culture at passage 2, dur-
ing log-growth and given intravenously. Just before cells
are trypsinized, they are rinsed with Tyrode’s salt solu-
tion then labeled with the vital dye, Dil at a concentra-
tion of 1 ug/ml in Tyrode’s for 20 minutes at 37°C. Dil
was initially diluted to 1 mg/ml in DMSO followed by
1:1000 diluted in Tyrode incubated for 20 minutes at
37°C. Each experimental run used hMSCs from a differ-
ent donor; 7 different hMSC preparations were used for
these studies.
Bone marrow derived macrophages (BMDM)
BMDM were utilized in a subset of studies (n = 3).
Briefly, bone marrow aspirates were obtained from syn-
geneic mice and cultured in the presence of L929 media
as previously defined [21].
Ceramic Cube Assay
Several in vitro assays for bone, cartilage, marrow
stroma, fat [22], and an in vivo assay [22,23] for the dif-
ferentiation of bone in porous calcium phosphate cera-
mic cubes (3 mm) have been used to test for the
differentiation potential and purity of the hMSCs [24].
The standard assay “the ceramic cube assay” for this dif-
ferentiation is the ability of hMSCs to form bone in
3-mm porous calcium phosphate cubes implanted sub-
cutaneously in mice. We have documented that a quan-
titative assessment of the amount of bone within the
pores of the cube is possible [24,25]. The purity of
hMSCs was defined as previously published [26,27].
Briefly, cubes measuring approximately 3 mm per side
were cut from a cylindrical ceramic rod composed of
40% hydroxyapatite and 60% tricalcium phosphate, gen-
erously provided by the Zimmer Corporation. The cubes
were washed with deionized water, dried, and then auto-
claved. The sterile cubes were immersed in a solution of
fibronectin at a concentration of 100 μg/ml. After a par-
tial vacuum was produced by withdrawing air through
the cap of the tube with a 30-ml syringe attached to a
22-gauge needle, the cubes were kept in the fibronectin
solution for 2 hours, after which they were allowed to
dry at room temperature. Human MSCs were trypsi-
nized as described above and resuspended in serum-free
medium at a concentration of 5 million cells per ml.
We load the cube with a suspension of 5 million cells
per ml, estimating the load volume to be 30-40 thou-
sand cells. Fibronectin-coated cubes were added to the
cell suspension and a partial vacuum was generated as
for the fibronectin coating [28,29]. Cell-loaded cubes
were then incubated at 37°C for two hours in a humidi-
fied atmosphere consisting of 5% CO2 and 95% air.
After the incubation period, the cubes were implanted
subcutaneously on the dorsal surface of severe compro-
mised immune deficient (SCID) mice. Mice were
anesthetized with a rodent cocktail consisting of keta-
mine, xylazine, and acepromazine as previously
described [19]. The skin and subcutaneous tissue at the
incision site was injected with Marcaine local anesthetic
at a concentration of 0.025%. After the incision was
made on the dorsal surface, up to 9 subcutaneous pock-
ets were expanded by blunt dissection. One cube was
placed in each pocket, and the incision was then closed
with wound clips. Animals were euthanized after 6
weeks and the cubes were fixed with 10% buffered for-
malin phosphate. The cube score decreases when
hMSCs are diluted with human dermal fibroblasts (non-
MSCs) which, are used for controls in these studies
[20,28]. We have published measurements of the secre-
tion of bioactive factors by hMSCs in growth, osteogen-
esis and in marrow stromagenesis pathways [30].
Neither the bioactive secretion assays [30] nor the cube
scores [20,25] provide potency assays for hMSCs. The
cube scores, however, provide the criteria for document-
ing the differentiation potential of hMSCs [31,32]. Table
1 provides the cube scores for the majority of the hMSC
preparations used in experiments reported here, show-
ing that the hMSCs appear to be typical [19].










1444 25 0.7 Not Done
1446 33 0.8 Not Done
1451 29 1.0 1.47
1450 51 0.8 1.29
1553 30 1.19 0.78
1557 47 1.0 1.11
1568 47 0.69 1.12
1594 28 0.79 1.17
1568 45 0.13 1.37
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Cytokine and Inflammatory Mediator Assessment
BAL and serum differentials were measured in duplicate
from each individual mouse (no samples were batched)
by cytospins and direct cell counts [33]. BAL level of
cytokines (R&D Systems, Minneapolis, MN) were
assessed by ELISAs and Luminex multiplex assays as
previously described [34]. Inter and intra assay variabil-
ity was controlled through the use of high and low qual-
ity control standards and standard curve slope
comparison using Statlia Technology (San Diego, CA).
The lower range of detection was between 3-10 pg/ml
depending on the cytokine in evaluation.
Statistics
Group and time point comparisons used repeated mea-
sures of analysis of variance (ANOVA) and t-tests. Indi-
vidual significance levels of 0.05 were used for all tests.
The designation of “n” in these studies is based upon
the number of experimental times the study was per-
formed. In each experiment, there were 4 groups: saline
challenged-no hMSCs, saline challenged-hMSCs, ovalbu-
min challenged-no hMSCs, ovalbumin challenged-
hMSCs. Groups were separated into histology/pathology
or bronchoalveolar lavage. Each group of histology/
pathology had 3-4 mice. Each group of inflammation
had 5-7 mice. Statistics were done based upon the total
number of experiments including all of the animals in
each of the different groups. In some instances a
description identifying “n” versus the numbers of ani-
mals in each group is explained for clarity.
Results
The Asthma Models
Balb/c mice were sensitized with OVA, and after 14
days the mice were challenged daily for 5 days with
either ovalbumin or sham PBS followed by sacrifice for
histology or BAL for inflammatory markers. The pul-
monary differential of the lungs of ovalbumin-treated
mice had significantly more eosinophils (Figure 1) and
an increase in total cell count, 25 ± 4% (n = 4, p =
0.04). Evaluation of lung histology in mice sensitized
and challenged with saline showed relatively little
change in lung morphology (1B) compared with ovalbu-
min-challenged mice, which showed significant epithelial
cell hyperplasia and thickening of the airway consistent
with other published observations of this model (1C).
Localization of Human Mesenchymal Stem Cells
Localization of hMSCs in the lung suggests a potential
therapeutic application to chronic lung diseases such as
asthma [13]. To further associate the ability of localizing
the hMSCs to the lungs of the mice in the asthma
model, hMSCs were labeled with the vital dye, Dil and
injected into mice. The animals were euthanized 6 days
after intravenous injection of the fluorescent hMSCs.
The lungs of the animals were snap frozen and frozen
sections were evaluated for the presence of labeled
hMSCs. Figure 2 shows an example in which Dil-stained
hMSCs were observed in the ovalbumin-challenged ani-
mal model, suggesting localization in the lung after
intravenous injection. Dil stained hMSCs were also
administered to saline challenged mice and evaluated
for distribution 6 days post administration. We could
detect no labeled hMSCs in the lungs of the saline chal-
lenged mice at 6 days. These studies implicate that in
inflammation, some of the hMSCs remain in the lung
whereas in the absence of inflammation the hMSCs con-
tinue elsewhere. Profiling the life of hMSCs in vivo in
the presence and absence of inflammation is the focus
of on-going studies in our laboratory. These results con-
firm previous observations when using rat models [13].
Human Stem Cells in Murine Models: Xenographic Effects
hMSCs were introduced by tail vein injection to mice
sensitized with ovalbumin and challenged with saline to
determine the impact of hMSCs in the absence of estab-
lished inflammation. These studies focus on defining the
impact of using human derived MSCs across species in
murine lungs. Figure 3 shows the change in total BAL
cell counts between ovalbumin-challenged and saline-
challenged mice in the acute model of asthma. Animals
with and without intravenous instillation of hMSCs
were studied. The differential between the naïve controls
and saline-challenged mice is minimal (data not shown).
hMSC therapy decreased the total cell recruitment in
the context of ovalbumin challenge (Figure 3A, p < 0.05,
n = 4) while increasing the total cell recruitment in the
acute saline-challenged model in the absence of inflam-
mation (Figure 3A, n = 4, p < 0.05). There was also a
change in the inflammatory status of the treated lung as
indicated by a decrease in macrophages (p = 0.05) and
an increase in neutrophils and eosinophils (Figure 3B, p
= 0.04, n = 4). Histologically there was no significant
difference between saline-challenged mice with or with-
out hMSCs (compare figure 3C with 3D+MSCs).
hMSC Effect on Murine Models of Asthma Inflammation
Mice were sensitized with ovalbumin and rested for 14
days. On day 14, hMSCs were administered to the ani-
mals intravenously followed by 5 daily challenges with
ovalbumin. The model resulted in increased eosinophils
and neutrophils with a decrease in macrophages consis-
tent with the acute asthma murine model (Figure 1).
Introduction of hMSCs in this model resulted in a
decrease in both neutrophils and eosinophils relative to
the ovalbumin-challenged control, and an increase in
numbers of macrophages in the BAL fluid of the mice
(Figure 4). Histologically, hMSC treatment resulted in a
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decrease in airway inflammation, mucus production and
epithelial cell lining thickening (4C) compared to ani-
mals not treated with hMSCs (4B). To further evaluate
the relationship between the hMSCs and the inflamma-
tion, we correlated the cube score values shown in
Table 1 with the overall total cell recruitment in the
ovalbumin-challenged model shown in Figure 3. The
percent (%) decrease in total cell recruitment in the
ovalbumin-challenged asthma model due to hMSC
administration was plotted against the cube score values
given in Table 1. Figure 4D shows that better differen-
tiation in the ceramic cube assay correlated with in vivo
decreased BAL total cell counts post-hMSC treatment
(r2 = 0.068, p = 0.02). The ceramic cube assay measures
osteo-differentiation as a measure of hMSC multipo-
tency. The correlation between immunomodulatory
activities in vivo provides an alternative means of evalu-
ating in vivo potency and efficacy. This is consistent
with the observations that the effect of hMSCs via para-
crine mechanisms or direct interaction with immune
cells, do not depend on cell engraftment and differentia-
tion (35, 36). Studies using a single hMSC preparation
in different preparations of the acute asthma model
were not done due to the requirement of large numbers,
Figure 1 Establishing the Acute Model of Murine Asthma. Mice were sensitized with ovalbumin, rested for 14 days and then challenged
daily with ovalbumin or sham PBS for 5 days. Mice were sacrificed and the lungs were processed for inflammation with BAL (1A) or histology
without BAL (1B saline-challenged (40×) versus 1C ovalbumin-challenged (40×)). Histology is representative of 5 different experiments with 6-8
mice in each group. Inflammation is representative of 5 different experiments with n = 4-6 for each group. Ovalbumin challenged mice had a
significant increase in inflammatory cells (n = 4, p = 0.04).
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issues of increased passage to generate these numbers,
time in culture and other potential environmental
induced changes in hMSC phenotype [37-39].
Administration of hMSCs Alters both Local and Systemic
Cytokines
Pulmonary Response
BAL fluid was obtained from the acute asthma model
mice with and without treatment with hMSCs. The
lavage fluid was evaluated for IFNg and essential cyto-
kines of inflammation and activation. The acute asthma
model had elevated IFNg relative to untreated mice
which was not detectable (n = 4, p < 0.05), which is
consistent with the literature [40]. Treatment of the ani-
mals with intravenous hMSCs, resulted in a statistical
decrease in BAL IFNg levels (Figure 5, n = 4, p = 0.05).
Systemic Response
The acute model of asthma had elevated levels of circu-
lating serum IL-1b relative to controls, whose levels
were not detectable (Figure 6A, n = 8, p < 0.001). IL-1b
levels decreased only if hMSCs were given after
initiation of inflammation (hMSCs given post challenge
on day 3, p < 0.05), not at the start of the acute chal-
lenge. IL-10, IL-5, IL-4 and IL-13 levels were not detect-
able in the murine model of acute asthma; systemic
levels of IFNg were only observed after treatment with
hMSCs (Figure 6B). The IFNg effect was dependent on
the presence of inflammation since saline animals given
hMSCs had no detectable circulating IFNg.
Dependence of The hMSC Effect on Existing Inflammation
To further investigate the potential of hMSCs to impact
inflammation at peak inflammation in the acute asthma
model, BAL was performed on mice treated with hMSCs
just prior to challenge (day 14) and post-3 days of chal-
lenge (day 16) (Figure 7, n = 5). There were no major dif-
ferences in BAL neutrophil or lymphocyte levels when
hMSCs were given either pre-challenge (before inflamma-
tion) or 3 days post -challenge (peak inflammation). Pre-
challenge mice had an increase in the number of mono-
cytes (C) and a decrease in the number of eosinophils (D,
n = 4, p = 0.05) compared to untreated mice. This “effect”
of the hMSCs was amplified by giving the hMSCs 3 days
post-challenge. While the eosinophils decreased in the
lung with the pre-treatment (D) and then with the post
day 3 treatment, the monocytes sequentially increase (C).
Furthermore, the lungs of the mice given the hMSCs 3
days post-secondary challenge had significantly more
monocytes than the untreated animals (n = 4, p = .05,
representative of 2 different experiments)
Discussion
hMSCs have the unique capacity to be both regenerative
and serve as conduits of mediators that can immuno-
modulate in situations of inflammation. Intravenously
injected hMSCs localize in the lung [13] prior to disse-
minating into the peripheral tissues. Asthma is an
inflammatory airway disease characterized by T-cell
hyper-reactivity, scarring and remodeling. Since hMSCs
have the capacity to inhibit scarring and suppress T-cell
activity, we investigated the potential of using hMSCs to
reverse airway inflammation in the murine ovalbumin
model of acute asthma. Our data show for the first time
that hMSCs are well tolerated in the murine model of
acute asthma, suggesting that hMSCs can favorably
change the outcome of asthmatic inflammation without
the pathology associated with cross-species application.
Further, our data show that hMSCs given after the
induction of airway disease dramatically reverse the air-
way inflammation associated with the ovalbumin model
of acute asthma. Additionally, the short-term nature of
the acute asthma model and the in vivo responsiveness
to hMSCs suggest that the acute model can be used to
measure hMSC effectiveness in vivo with the correlation
of the standard cube score with percent decrease in
Figure 2 Dil labeled hMSCs can be Localized in the Murine
Lung. Sensitized and challenged mice from the acute asthma
group were given hMSCs 5 days prior to euthanisia. The hMSCs
were labeled with the vital dye, Dil. The animals were assessed for
the presence of Dil fluorescent hMSCs. Highly positive hMSCs (white
arrows) were observed in the lung tissue of mice #11 and #26.
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Figure 3 Xenographic Effect of hMSCs on Total Cell Recruitment. Animals were sensitized with ovalbumin and challenged with saline
followed by BAL. The total differential cell count between saline-challenged mice and naive controls was negligible (data not shown). hMSC
exposure decreased the total cell count in the BAL of the ovalbumin-challenged mice (Figure 3A, p = 0.03, n = 5), but increased the total cell
count in the saline-challenged mice (Figure 3A, p < 0.05 for the saline control versus saline control with husks). Further, the hMSCs altered the
inflammatory phenotype of the saline control animal (3B, n = 4, p < 0.05) suggesting that the hMSCs can induced a cellular response in the
absence of ovalbumin-induced inflammation in the context of an acute response. The change in the inflammatory status did not impact the
immediate histology of the acute treated model (3C:40× and 3D:hMSC, 40×). Histology is representative of 5 different experiments with n = 6-8
in each group.
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Figure 4 hMSCs Decrease Acute Inflammation in the Acute Asthma Lung Model. hMSCs (106/100 ul injected) were given by tail vein
injection at day 14 post-sensitization. Mice were evaluated after 5 days of challenge for inflammation. Concurrent mice were evaluated
specifically for histology (Figure 4B and 4C). Treatment of the acute asthma mice with MSCs resulted in increased production of macrophages
and decreased production of neutrophils and eosinophils. Histologically, the epithelial lining of the bronchiolar airways appears to have less
thickening and less surrounding mucus (4C: 40×) when compared with animals not treated with hMSCs (4B: 40×). Histology is representative of
5 different experiments with 6-8 mice in each group. Inflammation is representative of 5 different experiments with n = 4-6 for each group. To
determine the relationship between response to hMSCs and the differentiation of the hMSCs, the percent change in total cellular recruitment
post-hMSC treatment was plotted against the cube score values in Table I (4D). Cube score values statistically correlated to percent decrease in
cellular recruitment (decrease in inflammation) with r2 = 0.68, p = 0.02, n = 7 different cube scores on n = 7 different hMSCs in 7 different
ovalbumin challenged asthma experiments.
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lung cell recruitment in response to antigenic challenge.
The ceramic cube assay measures osteo-differentiation
as a measure of hMSC multipotency and has, histori-
cally served as the gold standard. The correlation
between immunomodulatory activities in vivo provides
an alternative means of evaluating in vivo potency and
efficacy. This is consistent with the observations that the
effect of MSCs via paracrine mechanisms or direct inter-
action with immune cells, do not depend on cell
engraftment and differentiation [35,36]. Future studies
will include hMSC dose-response and different modes
of administration.
Adult hMSCs isolated from bone marrow are able to
differentiate in culture into a number of mesenchymal
phenotypes including those that form bone, cartilage,
muscle, fat and other connective tissues [23]. Originally,
it has been suggested that hMSCs are responsible for
the normal turnover and maintenance of adult mesench-
ymal tissues. More recently, hMSCs have been shown to
reside in a number of tissues as pericytes, suggesting
that they can have a major impact on focal injuries
[1,2,41]. If hMSC are capable of impacting the local
milieu, they could be used therapeutically as allogeneic
sources of repair in vivo [42]. The therapeutic implica-
tion of hMSCs is based upon the observation that cul-
ture-expanded hMSCs have no detectable MHC class II
cell surface markers or co-stimulator molecules [4], sug-
gesting that the hMSCs evade immune surveillance by
the host. In our model, hMSCs induce white blood cell
recruitment in the acute model when the animals lack
the inflammation associated with the secondary chal-
lenge with ovalbumin. Although the BAL differential
and the total cell counts were altered by hMSCs in the
acute control, no detectable changes in lung histology
are detected, suggesting the absence of adverse response
of the host tissue to the hMSCs in the saline-challenged
acute model.
hMSCs were first used to supplement bone marrow
transplantations because hMSCs were assumed to home
back to the bone marrow stroma and have the potential
to efficiently prefabricate the injured marrow stroma for
human stem cell engraftment and subsequent hemato-
poietic lineage functions [10]. Early successful clinical
trials supported the idea that culture-expanded hMSCs
were, indeed, capable of promoting successful engraft-
ment of hematopoietic progenitors and their production
of circulating mature blood cells efficiently and safely
[43,44]. Allogeneic engraftment has also been used to
treat gene defects [45,46]. In these cases, culture-
expanded hMSCs from the allo-donor were used to sup-
plement the bone marrow transplantation of host with
defective genotypes with the assumption that the
hMSCs homed to marrow and re-established the stroma
to enhance allogeneic engraftment. For example, Hor-
witz and colleagues reported improvement in six chil-
dren with osteogenesis imperfecta treated with
Figure 5 hMSCs Decrease IFNg in Acute Asthma. BAL fluid
obtained from mice modeled for acute asthma had significantly less
IFNg when treated with hMSCs in vivo (n = 4, p < 0.05).
Figure 6 Serum IL-1b Decreases with hMSC Treatment. Cardiac
puncture was done to obtain adequate serum samples from mice
with and without treatment with hMSCs. The acute asthma mice
had significantly elevated levels of systemic IL-1b (6A, n = 8, p <
0.001). Systemic IL-1b concentrations were altered by hMSCs in the
acute asthma model when hMSCs were given three days after
challenge (peak inflammation). hMSCs significantly decreased the
level of systemic IL-1b (n = 2, p = 0.05). Systemic IFNg
concentrations were increased in the acute asthma mice after hMSC
treatment (6B, n = 4, p = 0.043). This was dependent on the
presence of in vivo inflammation, since saline animals given hMSCs
had no detectable serum IFNg.
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allogeneic bone marrow transplantation [45]. These stu-
dies used allogeneic hMSCs with no adverse events. In
studies using the bleomycin model, administration of
hMSCs into mice immediately after exposure to bleomy-
cin was associated with a significant reduction in inflam-
mation and collagen deposition associated with the lung
disease [47,48]. In these studies, the rates of engraftment
were undetectable or at the limits of detection. The
implication is that the mechanism of the hMSC effect
and improvement in the bleomycin- induced inflamma-
tion was not particularly due to stem cell engraftment
of the injured tissue, but to the effects of paracrine
secretion of growth factors and cytokines which stimu-
late repair.
hMSCs have been shown to effectively shut down
graft versus host disease (GvDH), a T -cell mismatched
immune-mediated disease [49]. Osiris Therapeutics
http://www.osiristx.com has documented that during a
study of compassionate use of adult marrow-derived
culture-expanded allogeneic hMSCs in children with
steroid resistant GvHD, 7 out of 12 had complete
remission of GvHD at one month and 95% were alive at
6 months. In addition, 9 out of 12 had complete recov-
ery from their gastrointestinal GvHD, and the remaining
3 had their severity reduced to Grade I gastrointestinal
GvHD. The allogeneic MSCs in these studies, even with
the multiple infusions, induced no adverse events http://
www.osiristx.com. This is consistent with our observa-
tions using hMSCs in the saline sensitized, saline-chal-
lenged control mice. These mice had no change in lung
pathology and minimal change in inflammatory status as
defined by BAL differential. These and other studies
established that isolation and culture expansion is safe
with clinical benefit from the intravenous delivery of
allogeneic hMSCs. These observations suggest that the
trophic effects of hMSCs played a profound role in the
observed therapeutic benefit in all of the above studies.
In terms of a potential therapeutic, our data show that
hMSCs are effective at attenuating or reversing the
inflammation and pathology associated with acute
asthma in the ovalbumin murine model of this airway
disease. The acute model of murine asthma generated
Figure 7 Lung Inflammation Determines Response to hMSCs. BAL fluid was obtained from mice treated with hMSCs just prior to challenge
and initiation of inflammation (pre-) or 3 days after initiation of inflammation (post-). BAL differentials were obtained from each animal using
cytospins and Wright-Giemsa stain. Neutrophil counts are in panel A, lymphocytes in panel B, monocytes in panel C and eosinophils in panel D.
The first bar represents the differential in the model without hMSCs. No difference was observed in levels of neutrophils or lymphocytes after
hMSC treatment. Pre-challenged mice had a decrease in eosinophils (panel D, n = 4, p = 0.05) compared to control mice. This decrease in
eosinophils was amplified at post-treatment with hMSCs. Additionally, post-treatment mice had a significant increase in localized levels of
monocyte/macrophages (panel C, n = 2, p = 0.05, 4 animals used in each group for each experiment).
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increased pulmonary inflammation and histology consis-
tent with increased mucus production and eosinophils.
hMSC treatment of acute asthma mice resulted in
decreased airway inflammation as determined by BAL.
Histologically, the airways showed signs of decreased
epithelial lining thickening and mucus hyper-production.
hMSCs in culture secrete a variety of molecules, both
bioactive and extracellular matrix, in response to their
local environment and their activity status [7,8,50]. In
our studies, not only did hMSC in children decrease the
pathology and inflammation in the acute murine
asthma, but there was a significant decrease in lung
IFNg levels consistent with decreased immune activa-
tion. Systemically, administration of hMSCs increased
IFNg, while at the same time decreased IL-1b. These
studies suggest a mechanism by which IFNg/IL-1b levels
may alter the host inflammatory response in an allergic
setting through altering systemic cytokines. Unlike other
models [35], we did not detect IL-10, IL-5, IL-4 or IL-13
in the BAL fluid from our model, which may be due to
tissue localization instead of soluble secretion into the
BAL fluid. The differences may also be due to the
model of selection. This is the focus of on-going
research and future manuscripts. In addition to under-
standing how hMSCs regulate in vivo systemic and loca-
lized IFNg/IL-1b levels, our focus will also include
factors secreted by the hMSCs or by the host in
response to MSCs, which alter the course of asthma.
Some possible candidates include TGS-6, SDF-1, MPC-3
and Hif-1a [51,52].
Aerosolized corticosteroids are the standard anti-
inflammatory medication for asthmatics and are effec-
tive in most cases. However, a substantial number of
asthmatics remain symptomatic even with the addition
of steroid-saving long-acting beta[2]-adrenoreceptor
agonists [53]. Variability in immune challenge and
response to therapy makes asthma a difficult disease to
monitor and manage. Further, long term treatment of
patients with systemic corticosteroids for severe asthma
raises concerns due to the secondary effects of the ther-
apeutic. New treatment options targeting the pathophy-
siologic events causing development and persistence of
asthma are desired for these patients [54]. The presenta-
tion of hMSCs limits the field of damage or injury and
inhibits fibrosis or scarring at sites of injury in the oval-
bumin model of asthma. The infused hMSCs secrete
immuno-modulatory agents which deactivate T-cell sur-
veillance and chronic inflammatory processes [8]; thus,
allogeneic or xenogeneic MSCs can be therapeutically
effective. The data presented in this manuscript impli-
cate the trophic products of hMSCs in attenuating
inflammation in the acute asthma murine model. Addi-
tionally, the acute asthma model of inflammation may
be a viable option for gauging hMSC efficacy and
function in vivo in conjuction with in vitro assays such
as the ceramic cube model.
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